AllianceBernstein
ACET icon

AllianceBernstein’s Adicet Bio ACET Stock Holding History

AllianceBernstein’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,296
Closed -$86.3K – 3232
2024
Q1 		$86.3K Hold
2,296
– – ﹤0.01% 3038
2023
Q4 		$69.4K Sell
2,296
-238
-9% -$5.19K ﹤0.01% 3104
2023
Q3 		$55.5K Hold
2,534
– – ﹤0.01% 3128
2023
Q2 		$98.5K Buy
2,534
+603
+31% +$53.2K ﹤0.01% 3080
2023
Q1 		$178K Buy
1,931
+281
+17% +$35.3K ﹤0.01% 2937
2022
Q4 		$236K Hold
1,650
– – ﹤0.01% 2955
2022
Q3 		$375K Buy
1,650
+844
+105% +$214K ﹤0.01% 2770
2022
Q2 		$188K Buy
+806
New +$177K ﹤0.01% 3037
2020
Q2 		– Sell
-103
Closed -$12K – 3195
2020
Q1 		$12K Sell
103
-55
-35% -$8.16K ﹤0.01% 3119
2019
Q4 		$26K Hold
158
– – ﹤0.01% 3109
2019
Q3 		$156K Buy
158
+63
+66% +$70.3K ﹤0.01% 2999
2019
Q2 		$108K Buy
+95
New +$86.1K ﹤0.01% 3070

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

AllianceBernstein's ACET Position: Q2 2024 in Review

AllianceBernstein sold out of Adicet Bio (ACET) in Q2 2024, closing a stake of 2,296 shares — an estimated $86.3K sold.

AllianceBernstein first reported a position in ACET in Q2 2019 and held it in 12 quarters. The position peaked at $375K in Q3 2022. 86 funds tracked by Wall St. Rank hold ACET as of Q2 2024.

  • AllianceBernstein reported no remaining Adicet Bio position as of Q2 2024 after selling out during the quarter.
  • AllianceBernstein sold 2,296 Adicet Bio shares in Q2 2024, an estimated $86.3K.
  • AllianceBernstein first reported a position in Adicet Bio in Q2 2019 and held it in 12 quarters.
  • AllianceBernstein's Adicet Bio position peaked at $375K in Q3 2022.
  • 86 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2024.

Based on AllianceBernstein's 13F filing for Q2 2024, filed 14 Aug 2024.